Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Thomas Sell"'
Autor:
Carmen Aguilar, Mindaugas Pauzuolis, Malvika Pompaiah, Ehsan Vafadarnejad, Panagiota Arampatzi, Mara Fischer, Dominik Narres, Mastura Neyazi, Özge Kayisoglu, Thomas Sell, Nils Blüthgen, Markus Morkel, Armin Wiegering, Christoph-Thomas Germer, Stefan Kircher, Andreas Rosenwald, Antoine-Emmanuel Saliba, Sina Bartfeld
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-14 (2022)
The carcinogenic bacterium Helicobacter pylori infects gastric cells. Here, the authors show that H. pylori preferentially infects differentiated cells in the pit region of gastric units, and this relies on bacterial chemotaxis towards host cell-rele
Externí odkaz:
https://doaj.org/article/ab0c3cf3ec204eddbd4e5450e1ff1a10
Autor:
Florian Uhlitz, Philip Bischoff, Stefan Peidli, Anja Sieber, Alexandra Trinks, Mareen Lüthen, Benedikt Obermayer, Eric Blanc, Yana Ruchiy, Thomas Sell, Soulafa Mamlouk, Roberto Arsie, Tzu‐Ting Wei, Kathleen Klotz‐Noack, Roland F Schwarz, Birgit Sawitzki, Carsten Kamphues, Dieter Beule, Markus Landthaler, Christine Sers, David Horst, Nils Blüthgen, Markus Morkel
Publikováno v:
EMBO Molecular Medicine, Vol 13, Iss 10, Pp n/a-n/a (2021)
Abstract In colorectal cancer, oncogenic mutations transform a hierarchically organized and homeostatic epithelium into invasive cancer tissue lacking visible organization. We sought to define transcriptional states of colorectal cancer cells and sig
Externí odkaz:
https://doaj.org/article/cc6f299b784d44ffb0f05c6f27ba79b1
Autor:
Raphael Brandt, Thomas Sell, Mareen Lüthen, Florian Uhlitz, Bertram Klinger, Pamela Riemer, Claudia Giesecke-Thiel, Silvia Schulze, Ismail Amr El-Shimy, Desiree Kunkel, Beatrix Fauler, Thorsten Mielke, Norbert Mages, Bernhard G. Herrmann, Christine Sers, Nils Blüthgen, Markus Morkel
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-15 (2019)
KRASG12V and BRAFV600E are oncogenic mutations that activate ERK signalling. Here, the authors use single cell analysis in intestinal organoids and show that BRAFV600E activates ERK in all intestinal cell types, while KRASG12V induces ERK activation
Externí odkaz:
https://doaj.org/article/4dc8feb67d344b21b71aced69388d1f8
Autor:
Kathleen Klotz-Noack, Bertram Klinger, Maria Rivera, Natalie Bublitz, Florian Uhlitz, Pamela Riemer, Mareen Lüthen, Thomas Sell, Katharina Kasack, Bastian Gastl, Sylvia S.S. Ispasanie, Tincy Simon, Nicole Janssen, Matthias Schwab, Johannes Zuber, David Horst, Nils Blüthgen, Reinhold Schäfer, Markus Morkel, Christine Sers
Publikováno v:
Cell Reports, Vol 32, Iss 12, Pp 108184- (2020)
Summary: Oncoproteins such as the BRAFV600E kinase endow cancer cells with malignant properties, but they also create unique vulnerabilities. Targeting of BRAFV600E-driven cytoplasmic signaling networks has proved ineffective, as patients regularly r
Externí odkaz:
https://doaj.org/article/2950671e43df461fba99d304a2fcf743
Autor:
Thomas Sell, Christian Klotz, Matthias M. Fischer, Rosario Astaburuaga-García, Susanne Krug, Jarno Drost, Hans Clevers, Christine Sers, Markus Morkel, Nils Blüthgen
Publikováno v:
Journal of Cell Biology. 222
Colorectal cancer progression is intrinsically linked to stepwise deregulation of the intestinal differentiation trajectory. In this process, sequential mutations of APC, KRAS, TP53, and SMAD4 enable oncogenic signaling and establish the hallmarks of
Autor:
Monilola A. Olayioye, Roland E. Kontermann, Matthias Schwab, Markus Morkel, Christine Sers, Marc-H. Dahlke, Thomas E. Mürdter, Svetlana Kalmykova, Thomas Sell, Lennart Kühl, Nicole Janssen, Alexander Rau
Supplementary Figure from Triple Targeting of HER Receptors Overcomes Heregulin-mediated Resistance to EGFR Blockade in Colorectal Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d6eb7376f0863330d13475dae42b11e
https://doi.org/10.1158/1535-7163.22522407
https://doi.org/10.1158/1535-7163.22522407
Autor:
Monilola A. Olayioye, Roland E. Kontermann, Matthias Schwab, Markus Morkel, Christine Sers, Marc-H. Dahlke, Thomas E. Mürdter, Svetlana Kalmykova, Thomas Sell, Lennart Kühl, Nicole Janssen, Alexander Rau
Current treatment options for patients with advanced colorectal cancers include anti-EGFR/HER1 therapy with the blocking antibody cetuximab. Although a subset of patients with KRAS WT disease initially respond to the treatment, resistance develops in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac07161b78811188c6e65f85ea0017af
https://doi.org/10.1158/1535-7163.c.6543369
https://doi.org/10.1158/1535-7163.c.6543369
Autor:
Alexander Rau, Nicole Janssen, Lennart Kühl, Thomas Sell, Svetlana Kalmykova, Thomas E. Mürdter, Marc-H. Dahlke, Christine Sers, Markus Morkel, Matthias Schwab, Roland E. Kontermann, Monilola A. Olayioye
Publikováno v:
Molecular Cancer Therapeutics. 21:799-809
Current treatment options for patients with advanced colorectal cancers include anti-EGFR/HER1 therapy with the blocking antibody cetuximab. Although a subset of patients with KRAS WT disease initially respond to the treatment, resistance develops in
Autor:
Thomas Sell, Christian Klotz, Matthias M. Fischer, Rosario Astaburuaga-García, Susanne Krug, Jarno Drost, Hans Clevers, Markus Morkel, Nils Blüthgen
Colorectal cancer progression is intrinsically linked to stepwise deregulation of the intestinal differentiation trajectory. In this process, sequential mutations of APC/Wnt, KRAS, TP53 and SMAD4 stepwisely enable an oncogenic signalling network. Her
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::13f15f3f8973d3884634f66857e69d36
https://doi.org/10.1101/2022.04.07.487491
https://doi.org/10.1101/2022.04.07.487491
Autor:
Nils Blüthgen, Reinhold Schäfer, Thomas Sell, Florian Uhlitz, Bertram Klinger, Matthias Schwab, Johannes Zuber, Mareen Lüthen, Tincy Simon, Sylvia Ispasanie, Natalie Bublitz, Maria Rivera, Nicole Janssen, Bastian Gastl, Pamela Riemer, Kathleen Klotz-Noack, David Horst, Markus Morkel, Katharina Kasack, Christine Sers
Publikováno v:
Cell Reports, Vol 32, Iss 12, Pp 108184-(2020)
Summary: Oncoproteins such as the BRAFV600E kinase endow cancer cells with malignant properties, but they also create unique vulnerabilities. Targeting of BRAFV600E-driven cytoplasmic signaling networks has proved ineffective, as patients regularly r